Roguljic, H., Nincevic, V., Bojanic, K., Kuna, L., Smolic, R., Vcev, A. ... Smolic, M. (2021). Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Frontiers in Pharmacology, 12.. doi: 10.3389/fphar.2021.678546
Roguljic, Hrvoje, et al. "Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update." Frontiers in Pharmacology, vol. 12, 2021. https://doi.org/10.3389/fphar.2021.678546
Roguljic, Hrvoje, Vjera Nincevic, Kristina Bojanic, Lucija Kuna, Robert Smolic, Aleksandar Vcev, Dragan Primorac, Andrijana Vceva, George Y. Wu i Martina Smolic. "Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update." Frontiers in Pharmacology 12 (2021). https://doi.org/10.3389/fphar.2021.678546
Roguljic, H., et al. (2021) 'Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update', Frontiers in Pharmacology, 12. doi: 10.3389/fphar.2021.678546
Roguljic H, Nincevic V, Bojanic K, Kuna L, Smolic R, Vcev A, i sur.. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Frontiers in Pharmacology [Internet]. 2021. [pristupljeno 01.10.2024.];12. doi: 10.3389/fphar.2021.678546
H. Roguljic, et al., "Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update", Frontiers in Pharmacology, vol. 12, 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:396498. [Citirano: 01.10.2024.]